Last reviewed · How we verify
NCT05177172
Effect of Oat Compounds on Postprandial Glucose Response
NA trial testing High beta glucans in Healthy Subjects in 20 participants. Completed in 19 January 2022.
19 January 2022
Quick facts
| Lead sponsor | Lund University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 1 December 2021 |
| Primary completion | 19 January 2022 |
| Estimated completion | 19 January 2022 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- High beta glucans
- Low beta glucans
- Low beta glucans + low polar lipids
- Polar lipids
- Control
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
Sponsor
Lund University
Who can join
Adults 20 to 40, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this project we will investigate synergistic effects of oat polar lipids and beta glucans on postprandial glucose tolerance
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05177172
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other Lund University trials
Trials by the same sponsor.
- NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
- NCT07425925 — Digital Peer-support-based Anti-HIV Stigma Intervention Among Adolescents Living With HIV in Ethiopia · NA · recruiting
- NCT07407842 — UPSIDES - Recovery Through Peer Support · NA · enrolling by invitation
- NCT07141108 — Self-monitoring and Remote Monitoring of Chronic Pain in Primary Care - Using a Digital Tool to Improve Quality of Life · NA · recruiting
- NCT07025694 — Exercise Training Among Children With Cerebral Palsy to Increase Health and Well-being - A Feasibility Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05177172 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lund University
- Last refreshed: 21 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177172.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing